B and T lymphocyte attenuator

GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.

Home
Ligands
B and T lymphocyte attenuator (Human)

GtoPdb Ligand ID: 4891

Abbreviated name: BTLA

Synonyms: B- and T-lymphocyte attenuator | B- and T-lymphocyte-associated protein | CD272

Compound class: Endogenous peptide in human, mouse or rat

Comment: BTLA is a negative immunomodulator. Interaction of BTLA with TNFRSF14 (HVEM) constitutes an immune checkpoint which inhibits T cell-mediated immune responses. Dysregulated BTLA expression contributes to immunosuppression and progression of some cancers [3-6] by enabling tumour immune evasion. Immunotherapeutics that block the BTLA-HVEM checkpoint offer potential as anti-tumour agents [7-8]. In the setting of inflammatory diseases anti-BTLA antibodies can induce inhibitory signalling and T cell activation, and reduce cytokine secretion [1].

There is information confirming two anti-BTLA monoclonals that were progressed to clinical development: HFB200603 (HiFiBiO; Phase 1 NCT05789069, solid tumours) [2] and ANB032 (AnaptysBio; Phase 2 NCT05935085, atopic dermatitis; terminated due to insufficient efficacy) [1].

Species: Human

Immunopharmacology Comments
BTLA is principally expressed on T and B lymphocytes, dendritic cells and macrophages. Interaction with its binding partner HVEM constitutes a co-inhibitory (immunosuppressive) checkpoint that controls the activation of BTLA-expressing immune cells.

Immunopharmacology Comments

BTLA is principally expressed on T and B lymphocytes, dendritic cells and macrophages. Interaction with its binding partner HVEM constitutes a co-inhibitory (immunosuppressive) checkpoint that controls the activation of BTLA-expressing immune cells.